Table 2.
Demographic and clinical covariates in the independent validation cohort.
| Variable | Full cohort |
|---|---|
| Sample size | 27 |
| Male sex | 19 (70) |
| Age, yrs. (continuous) | 71 (66, 81) |
| Current ICI treatment | |
| Pembrolizumab monotherapy | 23 (85) |
| Ipilimumab/nivolumab combination | 4 (15) |
| Survival-related events | |
| Progression (PFS) event | 10 (37) |
| Death (OS) event | 9 (33) |
| Time to event, mos. (continuous) | |
| Progression | NR (9.9, NR) |
| Death | 18.6 (15.8, NR) |
| Best overall response | |
| Complete response | 5 (19) |
| Partial response | 5 (19) |
| Stable disease | 6 (22) |
| Progressive disease | 9 (33) |
| Missing | 2 (7) |
Counts are followed by the appropriate column-wise percentage, while continuous variables are summarized by medians and either IQRs or, for time to event variables, 95% confidence limits (NR, not reached).